Skip to content

Study · Not a test of the peptide alone · 2019

7 results

Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.

Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY

Seminars in arthritis and rheumatism10 Jan 2019Cited by 34 (Europe PMC)

PMID30737062 (opens in a new tab)DOI10.1016/j.semarthrit.2019.01.006 (opens in a new tab)PepBankPUB-30737062
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther

    In simulated women at increased fracture risk, sequential ABL/ALN cost less than sequential TPTD/ALN in all simulated populations.

    In plain wordsIn increased-fracture-risk simulations, ABL/ALN cost less than TPTD/ALN.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseModeled cost
    Study

    n: not reported in source

    Markov microsimulation of sequential osteoporosis treatment
    Comparator
    TPTD/ALN
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, higher QALYs) compared with sequential TPTD/ALN therapy, resulting from the improved efficacy and lower drug price of ABL.
    2 context sentences
    Summary · context
    A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of sequential ABL/ALN compared with sequential TPTD/ALN and no treatment with a lifetime horizon from the US payer perspective. Patients were assumed to receive ABL or TPTD for 18 months followed by 5…
    Summary · context
    Evaluation was completed for patients, aged 50-80 years with a BMD T-score ≤ -3.5 or with a T-score between -2.5 and -3.5 and a history of ≥ one osteoporotic fracture.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 02Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther

    In simulated women at increased fracture risk, sequential TPTD/ALN cost more than sequential ABL/ALN in all simulated populations.

    In plain wordsIn increased-fracture-risk simulations, TPTD/ALN cost more than ABL/ALN.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseModeled cost
    Study

    n: not reported in source

    Markov microsimulation of sequential osteoporosis treatment
    Comparator
    ABL/ALN
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, higher QALYs) compared with sequential TPTD/ALN therapy, resulting from the improved efficacy and lower drug price of ABL.
    2 context sentences
    Summary · context
    A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of sequential ABL/ALN compared with sequential TPTD/ALN and no treatment with a lifetime horizon from the US payer perspective. Patients were assumed to receive ABL or TPTD for 18 months followed by 5…
    Summary · context
    Evaluation was completed for patients, aged 50-80 years with a BMD T-score ≤ -3.5 or with a T-score between -2.5 and -3.5 and a history of ≥ one osteoporotic fracture.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther

    In simulated women at increased fracture risk, sequential ABL/ALN yielded higher QALYs than sequential TPTD/ALN in all simulated populations.

    In plain wordsIn increased-fracture-risk simulations, ABL/ALN yielded more quality-adjusted life-years than TPTD/ALN.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseModeled QALYs
    Study

    n: not reported in source

    Markov microsimulation of sequential osteoporosis treatment
    Comparator
    TPTD/ALN
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, higher QALYs) compared with sequential TPTD/ALN therapy, resulting from the improved efficacy and lower drug price of ABL.
    2 context sentences
    Summary · context
    A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of sequential ABL/ALN compared with sequential TPTD/ALN and no treatment with a lifetime horizon from the US payer perspective. Patients were assumed to receive ABL or TPTD for 18 months followed by 5…
    Summary · context
    Evaluation was completed for patients, aged 50-80 years with a BMD T-score ≤ -3.5 or with a T-score between -2.5 and -3.5 and a history of ≥ one osteoporotic fracture.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  4. 04Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther

    In simulated women at increased fracture risk, sequential TPTD/ALN yielded lower QALYs than sequential ABL/ALN in all simulated populations.

    In plain wordsIn increased-fracture-risk simulations, TPTD/ALN yielded fewer quality-adjusted life-years than ABL/ALN.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseModeled QALYs
    Study

    n: not reported in source

    Markov microsimulation of sequential osteoporosis treatment
    Comparator
    ABL/ALN
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, higher QALYs) compared with sequential TPTD/ALN therapy, resulting from the improved efficacy and lower drug price of ABL.
    2 context sentences
    Summary · context
    A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of sequential ABL/ALN compared with sequential TPTD/ALN and no treatment with a lifetime horizon from the US payer perspective. Patients were assumed to receive ABL or TPTD for 18 months followed by 5…
    Summary · context
    Evaluation was completed for patients, aged 50-80 years with a BMD T-score ≤ -3.5 or with a T-score between -2.5 and -3.5 and a history of ≥ one osteoporotic fracture.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 05Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther

    In probabilistic sensitivity analyses, ABL/ALN was dominant over TPTD/ALN in at least 99% of simulations.

    In plain wordsIn computer models, ABL/ALN had lower costs and higher quality-adjusted life-years than TPTD/ALN in at least 99% of simulations.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableSensitivity-analysis dominance
    Study

    n: not reported in source

    Markov microsimulation of sequential osteoporosis treatment
    Comparator
    TPTD/ALN
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Probabilistic sensitivity analyses suggested that ABL/ALN was dominant in at least 99% of the simulations.
    3 context sentences
    Summary · context
    In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, higher QALYs) compared with sequential TPTD/ALN therapy, resulting from the improved efficacy and lower drug price of ABL.
    Summary · context
    A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of sequential ABL/ALN compared with sequential TPTD/ALN and no treatment with a lifetime horizon from the US payer perspective. Patients were assumed to receive ABL or TPTD for 18 months followed by 5…
    Summary · context
    Evaluation was completed for patients, aged 50-80 years with a BMD T-score ≤ -3.5 or with a T-score between -2.5 and -3.5 and a history of ≥ one osteoporotic fracture.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  6. 06Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther

    In probabilistic sensitivity analyses, TPTD/ALN was dominated by ABL/ALN in at least 99% of simulations.

    In plain wordsIn computer models, TPTD/ALN had higher costs and lower quality-adjusted life-years than ABL/ALN in at least 99% of simulations.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableSensitivity-analysis dominance
    Study

    n: not reported in source

    Markov microsimulation of sequential osteoporosis treatment
    Comparator
    ABL/ALN
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Probabilistic sensitivity analyses suggested that ABL/ALN was dominant in at least 99% of the simulations.
    3 context sentences
    Summary · context
    In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, higher QALYs) compared with sequential TPTD/ALN therapy, resulting from the improved efficacy and lower drug price of ABL.
    Summary · context
    A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of sequential ABL/ALN compared with sequential TPTD/ALN and no treatment with a lifetime horizon from the US payer perspective. Patients were assumed to receive ABL or TPTD for 18 months followed by 5…
    Summary · context
    Evaluation was completed for patients, aged 50-80 years with a BMD T-score ≤ -3.5 or with a T-score between -2.5 and -3.5 and a history of ≥ one osteoporotic fracture.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  7. 07Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther

    In simulated women at increased fracture risk, ABL/ALN cost per QALY gained versus no treatment was always below $130,000.

    In plain wordsIn computer models, ABL/ALN cost below $130,000 per additional quality-adjusted life-year compared with no treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableCost per QALY gained
    Study

    n: not reported in source

    Markov microsimulation of sequential osteoporosis treatment
    Comparator
    No treatment
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Compared to no treatment, the cost per QALY gained of ABL/ALN was always below $130,000.
    2 context sentences
    Summary · context
    A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of sequential ABL/ALN compared with sequential TPTD/ALN and no treatment with a lifetime horizon from the US payer perspective. Patients were assumed to receive ABL or TPTD for 18 months followed by 5…
    Summary · context
    Evaluation was completed for patients, aged 50-80 years with a BMD T-score ≤ -3.5 or with a T-score between -2.5 and -3.5 and a history of ≥ one osteoporotic fracture.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.